Literature DB >> 1932294

Current status of a recombinant antihemophilic factor VIII clinical trial organized by Baxter.

I Scharrer1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1991        PMID： 1932294     DOI： 10.1007/bf01703250

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  1 in total

1.  Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia.

Authors:  G C White; C W McMillan; H S Kingdon; C B Shoemaker
Journal:  N Engl J Med       Date:  1989-01-19       Impact factor: 91.245
  1 in total
  2 in total

1.  Evaluation of genetic stability of recombinant human factor VIII by peptide mapping and on-line mass spectrometric analysis.

Authors:  M J Besman; D Shiba
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

Review 2.  Comparison of anaesthetic- and seizure-induced states of unconsciousness: a narrative review.

Authors:  Benjamin F Gruenbaum
Journal:  Br J Anaesth       Date:  2020-09-18       Impact factor: 9.166
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.